Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis

Experimental Neurology

Volumn 262, Issue Part A, 2014, Pages 66-71

  Varrin Doyer, Michel ^a   Zamvil, Scott S ^a   Schulze Topphoff, Ulf ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Disease modifying therapy; Experimental autoimmune encephalomyelitis; Immunomodulation; Laquinimod; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; LAQUINIMOD; PLACEBO; IMMUNOLOGIC FACTOR; QUINOLONE DERIVATIVE;

ABDOMINAL PAIN; AXONAL INJURY; BACKACHE; CLINICAL STUDY; COUGHING; DISEASE ASSOCIATION; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MULTIPLE SCLEROSIS; NONHUMAN; RELAPSE; REVIEW; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT PLANNING; ANIMAL; DISEASE MODEL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; QUINOLONES;

EID: 84908655755     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.04.002     Document Type: Review

References (39)

1. Aharoni R., Saada R., Eilam R., Hayardeny L., Sela M., Arnon R. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2012, 251:14-24.
2. Bomback A.S., Appel G.B. Updates on the treatment of lupus nephritis. J. Am. Soc. Nephrol. 2010, 21:2028-2035.
3. Bruck W., Wegner C. Insight into the mechanism of laquinimod action. J. Neurol. Sci. 2011, 306:173-179.
4. Bruck W., Zamvil S.S. Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis. Expert. Rev. Clin. Pharmacol. 2012, 5:245-256.
5. Bruck W., Pfortner R., Pham T., Zhang J., Hayardeny L., et al. Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012, 124:411-424.
6. Bruck W., Gold R., Lund B.T., Oreja-Guevara C., Pratt A., et al. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol. 2013, 70:1315-1324.
7. Brunmark C., Runstrom A., Ohlsson L., Sparre B., Brodin T., et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2002, 130:163-172.
8. Comi G., Pulizzi A., Rovaris M., Abramsky O., Arbizu T., et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 371:2085-2092.
9. Comi G., Abramsky O., Arbizu T., Boyko A., Gold R., et al. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult. Scler. 2010, 16:1360-1366.
10. Comi G., Jeffery D., Kappos L., Montalban X., Boyko A., et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 2012, 366:1000-1009.
11. Comi G., Vollmer T., Cutter G., Sasson N., Ladkani D., Gorfine T. Disease progression in relapse-free patients treated with laquinimod. Mult. Scler. 2013, 19(11 Suppl.):74-558. (P1036).
12. Dudziak D., Kamphorst A.O., Heidkamp G.F., Buchholz V.R., Trumpfheller C., et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007, 315:107-111.
13. Filippi M., Rocca M.A., Pagani E., De Stefano N., Jeffery D., et al. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J. Neurol. Neurosurg. Psychiatry 2013, [Epub ahead of print] PubMed PMID: 24029546.
14. Gurevich M., Gritzman T., Orbach R., Tuller T., Feldman A., Achiron A. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. J. Neuroimmunol. 2010, 221:87-94.
15. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.
16. Jolivel V., Luessi F., Masri J., Kraus S.H., Hubo M., et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain 2013, 136:1048-1066.
17. Jonsson S., Andersson G., Fex T., Fristedt T., Hedlund G., et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J. Med. Chem. 2004, 47:2075-2088.
18. Kalb R. The protean actions of neurotrophins and their receptors on the life and death of neurons. Trends Neurosci. 2005, 28:5-11.
19. Kuchroo V.K., Prabhu Das M., Brown J.A., Ranger A.M., Zamvil S.S., et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995, 80:707-718.
20. Kuchroo V.K., Anderson A.C., Waldner H., Munder M., Bettelli E., Nicholson L.B. T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu. Rev. Immunol. 2002, 20:101-123.
21. Linker R.A., Lee D.H., Demir S., Wiese S., Kruse N., et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 2010, 133:2248-2263.
22. Lund B.T., Kelland E.E., Hayardeny L., Barilan O., Gilmore W., Weiner L.P. Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod. J. Neuroimmunol. 2013, 263:108-115.
23. Magliozzi R., Howell O., Vora A., Serafini B., Nicholas R., et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007, 130:1089-1104.
24. Molnarfi N., Schulze-Topphoff U., Weber M.S., Patarroyo J.C., Prod'homme T., et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J. Exp. Med. 2013, 210:2921-2937.
25. Noseworthy J.H., Wolinsky J.S., Lublin F.D., Whitaker J.N., Linde A., et al. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 2000, 54:1726-1733.
26. Polman C., Barkhof F., Sandberg-Wollheim M., Linde A., Nordle O., Nederman T. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005, 64:987-991.
27. Schulze-Topphoff U., Shetty A., Varrin-Doyer M., Molnarfi N., Sagan S.A., et al. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS ONE 2012, 7:e33797.
28. Steinman L., Zamvil S.S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 2005, 26:565-571.
29. Thone J., Ellrichmann G., Seubert S., Peruga I., Lee D.H., et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am. J. Pathol. 2012, 180:267-274.
30. Toubi E., Nussbaum S., Staun-Ram E., Snir A., Melamed D., et al. Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis. J. Neuroimmunol. 2012, 251:45-54.
31. Vollmer T., Soelberg Sorensen P., Arnold D.L. A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis. Mult. Scler. J. 2011, 17:S507-S508. on behalf of the BRAVO Study Group.
32. Vollmer T., Montalban X., Comi G., Ziemssen T., Boyko A., Vermersch P., Sasson N., Gorfine T., Knappertz V., Filippi M. Multicentre, randomized, placebo controlled study to evaluate the efficacy, safety and tolerability of two doses of oral laquinimod. Mult. Scler. 2013, 19(11 Suppl.):74-558. (P1054).
33. Vollmer T.L., Sorensen P.S., Selmaj K., Zipp F., Havrdova E., et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J. Neurol. 2014, (Feb 18 Epub ahead of print PubMed PMID: 24535134).
34. Weber M.S, Prod'homme T., Youssef S., Dunn S.E., Rundle C.D., et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 2007, 13:935-943.
35. Wegner C., Stadelmann C., Pfortner R., Raymond E., Feigelson S., et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2010, 227:133-143.
36. Wolinsky J.S., Narayana P.A., Noseworthy J.H., Lublin F.D., Whitaker J.N., et al. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology 2000, 54:1734-1741.
37. Yang J.S., Xu L.Y., Xiao B.G., Hedlund G., Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol. 2004, 156:3-9.
38. Zamvil S.S., Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 1990, 8:579-621.
39. Zou L.P., Abbas N., Volkmann I., Nennesmo I., Levi M., et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 2002, 42:731-739.